Novo-Nordisk's Victoza Approved For Type-2 Diabetes In China (NVO).

by Benzinga Staff
March 22, 2011 7:45 AM | 10 seconds read |
Novo-Nordisk's Victoza Approved For Type-2 Diabetes In China (NVO). The Chinese State Food And Drug Administration has approved Novo-Nordisk's NVO Victoza for Type-2 diabetes treatment.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsLegalGlobalHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!